NYSE · Healthcare · Medical Devices · USA
Artivion Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures, particularly for patients with aortic disease. Its product portfolio includes aortic stent grafts, mechanical heart valves, surgical sealants, and cryopreserved cardiac and vascular tissues. The company operates through two segments: Medical Devices and Preservation Services, serving cardiac and vascular surgeons globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Artivion Inc stock.
Overvalued: intrinsic value $13.89 per share, market price $23.09, margin of safety -66.2% (as of 2026-10-20).
Discounting its cash flows at 10.0% values the shares at $13.89; the price of $23.09 is 66% above that value, and 73% of that value comes from beyond year five.
Leak Score: 39/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
29 more in this industry show a wider margin of safety.
AORT is overvalued (as of the 2026-10-20 close). Discounting its cash flows at 10.0% values the shares at $13.89; the price of $23.09 is 66% above that value, and 73% of that value comes from beyond year five.
$13.89 per share (as of the 2026-10-20 close), against a market price of $23.09. That is a margin of safety of -66.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
39 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.